Transition from esophagectomy to endoscopic therapy for early esophageal cancer. Issue 3 (15th July 2021)

• Record Type: Journal Article
• Authors: Dunn, Jason M; Reyhani, Arasteh; Santaolalla, Aida; Zylstra, Janine; Gimson, Eliza; Pennington, Mark; Baker, Cara; Kelly, Mark; Van Hemelrijck, Mieke; Lagergren, Jesper; Zeki, Sebastian S; Gossage, James A; Davies, Andrew R
• Is Part Of: Diseases of the esophagus. Volume 35:Issue 3(2022)
• Publication Date: 2021-07-15
• Subjects: Early esophageal cancer -- Esophagus -- Early cancer -- Esophagectomy -- Endoscopic therapy -- Endoscopic mucosal resection; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1093/dote/doab047
• Languages: English
• ISSNs: 1120-8694

Abstract

Summary: Background: To assess the outcomes of patients with early esophageal cancer and high-grade dysplasia comparing esophagectomy, the historical treatment of choice, to endoscopic eradication therapy (EET). Methods: Retrospective cohort study of consecutive patients with early esophageal cancer/high-grade dysplasia, treated between 2000 and 2018 at a tertiary center. Primary outcomes were all-cause and disease-specific mortality assessed by multivariable Cox regression and a propensity score matching sub analysis, providing hazard ratios (HR) with 95% confidence intervals (CI) adjusted for age, tumor grade (G1/2 vs. G3), tumor stage, and lymphovascular invasion. Secondary outcomes included complications, hospital stay, and overall costs. Results: Among 269 patients, 133 underwent esophagectomy and 136 received EET. Adjusted survival analysis showed no difference between groups regarding all-cause mortality (HR 1.85, 95% CI 0.73, 4.72) and disease-specific mortality (HR 1.10, 95% CI 0.26, 4.65). In-hospital and 30-day mortality was 0% in both groups. The surgical group had a significantly higher rate of complications (Clavien–Dindo ≥3 26.3% vs. endoscopic therapy 0.74%), longer in-patient stay (median 14 vs. 0 days endoscopic therapy) and higher hospital costs(£16 360 vs. £8786 per patient). Conclusion: This series of patients treated during a transition period from surgery to EET, demonstrates a primary endoscopic approach does not compromise oncological outcomes with the benefit of fewer complications, shorter hospital stays, and lower costs compared to surgery. It should be available as the gold standard treatment for patients with early esophageal cancer. Those with adverse prognostic features may still benefit from esophagectomy.